

May 16, 2026

The General Manager, Department of Corporate Services Bombay Stock Exchange Ltd (BSE) Phiroze Jheejeebhoy Towers, Dalal Street, Mumbai - 400 001. Scrip Code - 543308 ISIN: INE967H01025	The Manager, Listing Department National Stock Exchange of India Limited, Exchange Plaza, 5th Floor, Plot No.C/1, 'G' Block Bandra - Kurla Complex Mumbai - 400 051. Symbol - KIMS ISIN: INE967H01025
--	--

Dear Sir/ Madam,

Subject: Compliance with Regulation 47 of the SEBI (Listing Obligation and Disclosure Requirement) Regulations, 2015

Pursuant to the provisions of Regulation 47 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, Please find enclosed a copy of the newspaper publication on the audited (Standalone and Consolidated) financial results of the company for the quarter and financial year ended 31st March 2026, published in Financial Express (English) and Navatelangana (Telugu).

The said publication may also be accessed on the website of the company i.e., <https://www.kimshospitals.com/investors/Disclosures> under Regulation 46 of SEBI (LODR) Regulations, 2015/ Newspaper advertisements.

We request you to take this on record.

Thanking you,

Yours truly

For Krishna Institute of Medical Sciences Limited

Nagajayanthi J.R

Company Secretary & Compliance Officer

Encl: As above

Krishna Institute of Medical Sciences Limited

D.No.: 1-8-31/1, Minister Road, Secunderabad - 500 003, Telangana, India
Phone: +91 40 4488 5000/4488 5184 | Fax: +91-40-27840980 | kimshospitals.com
CIN: L55101TG1973PLC040558

altiva SIF

— By Edelweiss Mutual Fund —

Edelweiss House, Off C.S.T Road, Kalina, Mumbai – 400098

NOTICE CUM ADDENDUM TO THE INVESTMENT STRATEGY INFORMATION DOCUMENT (ISID) AND KEY INFORMATION MEMORANDUM (KIM) AND STATEMENT OF ADDITIONAL INFORMATION (SAI) OF THE INVESTMENT STRATEGY OF ALTIVA SPECIALISED INVESTMENT FUND

RECORD DATE FOR DISTRIBUTION UNDER INCOME DISTRIBUTION CUM CAPITAL WITHDRAWAL OPTION (IDCW OPTION)

NOTICE is hereby given that Edelweiss Trusteeship Company Limited, Trustee to Altiva SIF, has approved declaration of IDCW Options under the following strategy of Altiva SIF, as per the details given below:

Name of the Strategy	Amount of IDCW*	Record Date	NAV per unit as on May 14, 2026 (Face Value ₹ 10 per unit)	Face Value per unit
Altiva Hybrid Long-Short Fund - Regular Plan IDCW Option	0.05	Wednesday, May 20, 2026**	10.3869	₹ 10.00
Altiva Hybrid Long-Short Fund - Direct Plan IDCW Option	0.05		10.4463	

Pursuant to payment of IDCW, the NAV of the aforementioned IDCW Options of the Strategy will fall to the extent of payout and statutory levy, if any.

*Distribution of the above IDCW is subject to availability of distributable surplus as on the Record Date and as reduced by the amount of applicable statutory levy, if any. Considering the volatile nature of the markets, the Trustee reserves the right to restrict the quantum of IDCW upto the per unit distributable surplus available under the Strategy on the Record Date in case of fall in the market.

**or the immediately following Business Day if that day is a Non-Business Day.

All Unit holders whose name appears in the Register of Unit holders of the aforementioned IDCW Options of the Strategy as at the close of business hours on the Record Date shall be eligible to receive the IDCW so declared.

Investors are requested to take note of the above.

For Edelweiss Asset Management Limited
Sd/-
Radhika Gupta
Managing Director & CEO
(DIN: 02657595)

Place : Mumbai
Date : May 15, 2026


For more information please contact:
Edelweiss Asset Management Limited
CIN: U65991MH2007PLC173409

Registered Office & Corporate Office: Edelweiss House, Off C.S.T Road, Kalina, Mumbai - 400098.
Tel No:- +91 22 4097 9737, Toll Free No. 1800 425 0090 (MTNL/BSNL), Non Toll Free No. 91 40 23001181,
Fax: +91 22 40979878, Website: www.edelweissmf.com/altivasif

INVESTMENTS IN SPECIALIZED INVESTMENT FUND INVOLVES RELATIVELY HIGHER RISK INCLUDING POTENTIAL LOSS OF CAPITAL, LIQUIDITY RISK AND MARKET VOLATILITY. PLEASE READ ALL INVESTMENT STRATEGY RELATED DOCUMENTS CAREFULLY BEFORE MAKING THE INVESTMENT DECISION.

THE BUSINESS DAILY FOR DAILY BUSINESS

FINANCIAL EXPRESS
Read to Lead



AZAD ENGINEERING LIMITED

STATEMENT OF AUDITED FINANCIAL RESULTS FOR THE QUARTER AND YEAR ENDED MARCH 31, 2026

₹ In Millions except for EPS/DPS


Particulars	Standalone					Consolidated				
	Quarter Ended		Year Ended			Quarter Ended		Year Ended		
	31-03-2026 (Audited)	31-12-2025 (Unaudited)	31-03-2025 (Audited)	31-03-2026 (Audited)	31-03-2025 (Audited)	31-03-2026 (Audited)	31-12-2025 (Unaudited)	31-03-2025 (Audited)	31-03-2026 (Audited)	31-03-2025 (Audited)
Total Income from Operations	1744.32	1644.26	1282.98	6379.08	4644.77	1781.20	1668.56	1303.04	6486.29	4679.45
Net Profit/(Loss) for the period/year (before tax and exceptional items)	491.40	471.02	367.87	1854.85	1260.17	512.35	477.76	358.78	1873.06	1240.26
Net Profit/(Loss) for the period/year before tax (after exceptional items)	491.40	471.02	367.87	1854.85	1260.17	512.35	477.76	358.78	1873.06	1240.26
Net Profit/(Loss) for the period/year after tax (after exceptional items)	351.29	340.43	260.34	1321.61	885.25	368.05	347.17	248.09	1335.63	865.34
Total Comprehensive Income for the period/year	355.33	335.30	262.66	1321.33	884.31	372.12	342.34	250.41	1335.68	864.40
Equity Share Capital	129.16	129.16	129.16	129.16	129.16	129.16	129.16	129.16	129.16	129.16
*Earnings Per Share of ₹ 2/- each										
a) Basic *	5.44	5.27	4.28	20.46	14.87	5.57	5.34	4.15	20.57	14.66
b) Diluted	5.44	5.27	4.28	20.46	14.87	5.57	5.34	4.15	20.57	14.66

Note:
1. The above is an extract of the detailed format of the Audited Standalone and Consolidated financial results for the quarter and year ended on March 31, 2026 filed with the stock exchange under regulation 33 of the SEBI (Listing and Other Disclosure Requirements) Regulations, 2015. The full format of the Audited Standalone and Consolidated financial results for the quarter and year ended on March 31, 2026 are available for investors at www.azad.in, www.bseindia.com, www.nseindia.com.

For and on behalf of Directors
Azad Engineering Limited
Sd/-
Rakesh Chopdar
Chairman and CEO
DIN: 01795599

Place: Hyderabad
Date: May 15, 2026

Registered Office: 90/C, 90/D, Phase 1 I.D.A, Jeedimetla, Hyderabad, Telangana, India, 500055
Phone: 040-23097007 | Email: info@azad.in | Website: www.azad.in | CIN No: L74210TG1983PLC004132



NOVARTIS INDIA LIMITED

Registered Office: Inspire BKC, 7th Floor, Bandra Kurla Complex, Bandra (East), Mumbai - 400 051 Tel.: +91 22 50243000; Email: india.investors@novartis.com; Website: www.novartis.in; CIN: L24200MH1947PLC006104

INFORMATION REGARDING THE NOTICE OF POSTAL BALLOT ISSUED FOR APPOINTMENT OF MS. GOWREE GOKHALE (DIN: 09351661) AS AN INDEPENDENT DIRECTOR DATED APRIL 16, 2026

Members are hereby informed that this is in reference to the Postal Ballot Notice of Novartis India Limited ("the Company") dated April 16, 2026, which was dispatched on the same date to all shareholders whose email addresses are registered with the Company/Depository Participants, and subsequently published in newspaper on April 17, 2026.

It has come to the Company's attention that an inadvertent error has occurred in the Notice and the Explanatory Statement relating to Special Business under Agenda Item No. 01. The correction is as follows: -


On page no. 2 of the Notice of Postal Ballot above the resolution for the appointment of Ms. Gowree Gokhale; on page no. 11 of the Explanatory Statement to the Notice of Postal Ballot, in the 2nd and 3rd paragraphs; and on page no. 12, in the last paragraph of the detailed profile of Ms. Gowree Gokhale, it has been inadvertently mentioned that the resolution shall be passed as an "Ordinary Resolution" instead of a "Special Resolution."

All other contents of the Postal Ballot Notice remain unchanged. Shareholders are requested to take note of the above correction and consider Item No. 1 under Special Business as a Special Resolution. This corrigendum and Revised Notice of the Postal Ballot is also available on the website of the Company at <https://www.novartis.com/in-en/investors-corporate-governance/novartis-india-limited-annual-general-meeting>

This communication is being issued for the information and benefit of all members in compliance with the applicable circulars.

For Novartis India Limited
Sd/-
Chandni Maru
Company Secretary and Compliance Officer
M. No- ACS 60291

Date : May 16, 2026
Place : Mumbai



KRISHNA INSTITUTE OF MEDICAL SCIENCES LIMITED

Corporate Identity Number : L55101TG1973PLC040558
Registered office : 1-8-31/1, Minister Road, Secunderabad - 500003, Telangana, India
Website: www.kimshospitals.com, Email: cs@kimshospitals.com, Tel: 040 7122 5000

STATEMENT OF AUDITED STANDALONE AND CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER AND YEAR ENDED 31 MARCH 2026


(Rupees in Millions)

S.No.	Particulars	Standalone					Consolidated				
		Quarter Ended		Year ended			Quarter Ended		Year ended		
		31-Mar-26 (Audited)	31-Dec-25 (Unaudited)	31-Mar-25 (Audited)	31-Mar-26 (Audited)	31-Mar-25 (Audited)	31-Mar-26 (Audited)	31-Dec-25 (Unaudited)	31-Mar-25 (Audited)	31-Mar-26 (Audited)	31-Mar-25 (Audited)
1	Total Income	4,738	4,562	3,701	17,581	14,408	10,843	10,029	8,014	39,308	30,670
2	Net profit (Before tax and Exceptional items)	958	978	1,097	3,597	3,923	657	686	1,232	3,451	5,473
3	Net profit before tax (after Exceptional items)	891	978	1,205	3,527	4,031	548	686	1,340	3,339	5,581
4	Net profit (after tax and Exceptional items)	659	725	935	2,607	3,029	331	519	1,061	2,420	4,148
5	Total comprehensive income for the period/year (Comprising income for the period/year (after tax) and other comprehensive income(after tax))	660	725	943	2,607	3,016	335	519	1,069	2,422	4,125
6	Equity share capital (Face value of Rs. 2/- each)				800	800				800	800
7	Reserves (excluding revaluation reserve)				23,487	20,880				21,674	20,578
8	Earnings per share (Face value of Rs. 2/- Each): (not annualised for the quarter ended)										
	(a) Basic (Rs.)	1.65	1.81	2.34	6.52	7.57	1.06	1.33	2.54	6.03	9.61
	(b) Diluted (Rs.)	1.65	1.81	2.34	6.52	7.57	1.06	1.33	2.54	6.03	9.61

Note:
1. The above is an extract of detailed Audited Financial Results filed with Stock Exchanges under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015. The full format of the Financial Results for the quarter and year ended 31 March 2026 are available on Stock Exchange(s) website www.bseindia.com, www.nseindia.com and on Company's website at www.kimshospitals.com.
2. The above results of the Company have been reviewed by the audit committee and approved by the Board of Directors at their meeting held on 15 May 2026.

By Order of the Board
For Krishna Institute of Medical Sciences Limited
Dr. B Bhaskara Rao
Chairman & Managing Director
DIN: 00008985

Place: Hyderabad
Date: 15 May 2026



ALIVUS LIFE SCIENCES LIMITED

(formerly Glenmark Life Sciences Limited)
Registered Office: Plot No. 170-172, Chandramouli Industrial Estate, Mohol Bazarpath, Solapur-413 213, India.
Corporate Office: Technopolis Knowledge Park, A Wing, Office No. 401 to 407, 4th Floor, Mahakali Caves Road, Andheri (E), Mumbai 400093 Phone No.: +91 22 68297979; CIN: L74900PN2011PLC139963
Website: www.alivus.com; Email: complianceofficer@alivus.com

EXTRACT OF AUDITED FINANCIAL RESULTS FOR THE QUARTER AND YEAR ENDED 31st MARCH, 2026

(₹ in Million, unless otherwise stated)

Sr. No.	Particulars	Quarter Ended		Year Ended	
		31 Mar'26	31 Mar'25	31 Mar'26	31 Mar'25
1.	Revenue from Operations	6,891.17	6,495.45	25,518.32	23,868.84
2.	Profit before exceptional items and tax	2,157.99	1,912.90	7,769.66	6,541.31
3.	Exceptional item	-	-	256.57	-
4.	Profit before tax	2,157.99	1,912.90	7,513.09	6,541.31
5.	Net Profit after tax	1,626.61	1,418.68	5,644.83	4,856.27
6.	Total Comprehensive income	1,639.43	1,417.17	5,657.07	4,843.79
7.	Paid up Equity Share Capital (face value of Rs. 2 each)	245.47	245.07	245.47	245.07
8.	Total Reserves	33,075.85	27,928.65	33,075.85	27,928.65
9.	Earnings per Equity Share				
	Basic (in Rs.)	13.23	11.57	45.99	39.63
	Diluted (in Rs.)	13.22	11.55	45.90	39.52

Notes:
1. The financial results have been prepared in accordance with the Indian Accounting Standard prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended).
2. The above Financial Results were reviewed by the Audit Committee at their meeting held on May 14, 2026 and thereafter approved and taken on record by the Board of Directors at their meeting held on May 14, 2026. The results have been subjected to Audit by Walker Chandorkar & Co LLP, the Statutory Auditor of the Company, who have expressed an unmodified opinion on the said results.
3. The above is an extract of the detailed format of audited financial results filed with the Stock Exchanges under Regulations 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full format of the audited financial results are available on the websites of the Stock Exchanges i.e. BSE Limited (www.bseindia.com) and National Stock Exchange of India Limited (www.nseindia.com) and also on the Company's website (www.alivus.com)

The Results along with the Auditor's Report have been uploaded on the Company's website at <https://www.alivus.com/investors/financial-results/> and can be accessed by scanning the QR code.

For Alivus Life Sciences Limited
(formerly Glenmark Life Sciences Limited)
Yasir Rawjee
Managing Director & CEO
DIN: 01965174

Mumbai, May 14, 2026

epaper.financialexpress.com

HYDERABAD

